Human African trypanosomiasis

The University of North Carolina at Chapel Hill

The University of North Carolina at Chapel Hill and more specifically its Department of Pathology and Laboratory Medicine in the School of Medicine leads an international consortium of researchers in the development of new drugs for the treatment of sleeping sickness and leishmaniasis, two diseases that are infecting and killing millions of people in developing nations. The consortium was initially supported by a $15.1 million five-year grant awarded by the Bill & Melinda Gates Foundation. It brings together some of the world's top experts in drug development and delivery to target the two devastating parasitic diseases. The consortium involves scientists from UNC-Chapel Hill as well as Georgia State University, the London School of Hygiene and Tropical Medicine, Ohio State University, the Swiss Tropical and Public Health Institute, the Kenya Trypanosomiasis Research Institute, and Immtech International, Inc. An additional grant in the amount of 22.6 US million dollars has been allocated in September 2006 to pursue this research.

Share